Tongue and Skin Hyperpigmentation During PEG-Interferon-α/Ribavirin Therapy in Dark-Skinned Non-Caucasian Patients with Chronic Hepatitis C
Tongue and Skin Hyperpigmentation During PEG-Interferon-α/Ribavirin Therapy in Dark-Skinned Non-Caucasian Patients with Chronic Hepatitis C
复制标题
深色皮肤非白种人慢性丙型肝炎患者在 PEG-干扰素-α/利巴韦林治疗期间舌头和皮肤色素沉着过度
DOI：
10.1111/j.1572-0241.2005.00323.x
复制
发表时间：
2006
期刊：
影响因子：
--
通讯作者：
P. Ferenci
中科院分区：
文献类型：
--
作者：
Calin Gurguta;C. Kauer;U. Bergholz;E. Formann;P. Steindl‐Munda;P. Ferenci
在使用干扰素 (IFN) 和利巴韦林 (RBV) 抗病毒治疗慢性丙型肝炎期间，可能会出现各种皮肤疾病。据我们所知，本文介绍了 5 名深色皮肤丙型肝炎病毒 (HCV) 患者在聚乙二醇化 (PEG)-IFN/RBV 联合治疗期间舌色素沉着过度的第一份报告。抗病毒治疗期间的舌色素沉着与年龄、性别、HCV 基因型、RBV 剂量、治疗持续时间或治疗结果无关。由于IFN增加α-黑素细胞刺激激素（MSH）表面受体的表达，因此使用具有较长血浆半衰期的PEG-IFN甚至可能增加此类皮肤副作用的发生率，特别是在深色皮肤的HCV患者中。
Various skin disorders may occur during antiviral therapy with interferon (IFN) and ribavirin (RBV) for chronic hepatitis C. This article describes to our knowledge the first report of lingual hyperpigmentation during pegylated (PEG)-IFN/RBV combination therapy in five dark-skinned hepatitis C virus (HCV) patients. Lingual pigmentation during antiviral therapy was not associated with age, gender, HCV genotype, doses of RBV, or duration of the treatment or treatment outcome. Since IFN increases the expression of α-melanocyte-stimulating hormone (MSH) surface receptors, the use of PEG-IFN having a longer plasma half-life may even increase incidence for such cutaneous side effects particularly in dark-skinned HCV patients.